North America pharmaceutical manufacturing industry is expected to grow by 11.0% annually in the forecast period and reach $241.76 billion by 2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.
Highlighted with 26 tables and 60 figures, this 125-page report 鈥淣orth America Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity鈥 is based on a comprehensive research of the entire North America pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥 Industry Structure
鈥 Growth Drivers
鈥 Restraints and Challenges
鈥 Emerging Product Trends & Industry Opportunities
鈥 Porter鈥檚 Fiver Forces
The trend and outlook of North America industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.
Based on Formulation, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
鈥 Tablets
鈥 Capsules
鈥 Injectable
鈥 Sprays
鈥 Suspensions
鈥 Powders
鈥 Other Formulations
Based on Route of Administration, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
鈥 Oral Medicine
鈥 Topical Medicine
鈥 Parenteral Medicine
鈥 Inhalations
鈥 Other Routes of Administration
Based on Age Group, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
鈥 Children & Adolescents
鈥 Adults
鈥 Geriatric
Based on Therapeutic Application, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
鈥 Cardiovascular Diseases
鈥 Pain
鈥 Diabetes
鈥 Cancer
鈥 Respiratory Diseases
鈥 Neurological Diseases
鈥 Orthopedics
鈥 Other Applications
Based on Drug Type, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
鈥 Branded Prescription Drugs
鈥 Generic Prescription Drugs
鈥 OTC Drugs
Based on Distribution Channels, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
鈥 Retail Channels
鈥 Non-retail Channels
Based on Manufacturing Facility, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
鈥 In-house Facility
鈥 Outsourced Facility
Geographically, the following national/local markets are fully investigated:
鈥 U.S.
鈥 Canada
鈥 Mexico
For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players.
Specifically, potential risks associated with investing in North America pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Industry Research Methodology 11
1.2.2 Industry Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Industry Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Industry Overview and Dynamics 20
2.1 Industry Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Industry 24
2.2 Major Growth Drivers 26
2.3 Industry Restraints and Challenges 29
2.4 Emerging Opportunities and Industry Trends 32
2.5 Porter鈥檚 Fiver Forces Analysis 36
3 Segmentation of North America Industry by Formulation 40
3.1 Industry Overview by Formulation 40
3.2 Tablets 42
3.3 Capsules 43
3.4 Injectable 44
3.5 Sprays 45
3.6 Suspensions 46
3.7 Powders 47
3.8 Other Formulations 48
4 Segmentation of North America Industry by Route of Administration 49
4.1 Industry Overview by Route of Administration 49
4.2 Oral Medicine 51
4.3 Topical Medicine 52
4.4 Parenteral Medicine 53
4.5 Inhalations 54
4.6 Other Routes of Administration 55
5 Segmentation of North America Industry by Age Group 56
5.1 Industry Overview by Age Group 56
5.2 Children & Adolescents 58
5.3 Adults 59
5.4 Geriatric 60
6 Segmentation of North America Industry by Therapeutic Application 61
6.1 Industry Overview by Therapeutic Application 61
6.2 Cardiovascular Diseases 63
6.3 Pain 64
6.4 Diabetes 65
6.5 Cancer 66
6.6 Respiratory Diseases 67
6.7 Neurological Diseases 68
6.8 Orthopedics 69
6.9 Other Applications 70
7 Segmentation of North America Industry by Drug Type 71
7.1 Industry Overview by Drug Type 71
7.2 Branded Prescription Drugs 73
7.3 Generic Prescription Drugs 74
7.4 OTC Drugs 75
8 Segmentation of North America Industry by Distribution Channels 76
8.1 Industry Overview by Distribution Channels 76
8.2 Retail Channels 78
8.3 Non-retail Channels 79
9 Segmentation of North America Industry by Manufacturing Facility 80
9.1 Industry Overview by Manufacturing Facility 80
9.2 In-house Facility 82
9.3 Outsourced Facility 83
10 North America Industry 2020-2027 by Country 84
10.1 Overview of North America Industry 84
10.2 U.S. 87
10.3 Canada 91
10.4 Mexico 93
11 Competitive Landscape 95
11.1 Overview of Key Vendors 95
11.2 New Product Launch, Partnership, Investment, and M&A 98
11.3 Company Profiles 99
Abbott Laboratories 99
Aenova Group 101
Amgen 102
AstraZeneca 103
Catalent Inc. 104
Eli Lilly and Company 105
F. Hoffmann-La Roche Ltd. 106
Gilead Sciences 107
GlaxoSmithKline plc 108
Johnson & Johnson 109
Lonza Group 110
Lupin 111
Merck & Co., Inc. 112
Novartis AG 113
Novo Nordisk 114
Pfizer, Inc. 115
Roche 116
Sanofi SA 117
Takeda 118
12 Investing in North America Industry: Risk Assessment and Management 119
12.1 Risk Evaluation of North America Industry 119
12.2 Critical Success Factors (CSFs) 122
Related Reports and Products 125
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda
听
听
*If Applicable.
